A Study to Evaluate the Safety and Immunogenicity of Ad5-105K in Adults Aged 18 to 49 Years

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

PHASE1

Total Enrollment

36 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-11-13

Study Completion Date

2026-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a randomized, observer-blind, positive-controlled study. There will be 2 treatment groups (Group A and B). In each treatment group, 18 participants will be randomly assigned to receive either the investigational vaccine (Dose A or Dose B of Ad5-105K) or a placebo in a ratio of 2:1. The distribution of participant's gender and age should be balanced in each group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study to Evaluate the Efficacy of GlaxoSmithKline (GSK) Biologicals' Candidate Tuberculosis (TB) Vaccine in Adults

NCT01755598

Tuberculosis Tuberculosis Vaccines

COMPLETED PHASE2

A Safety and Immunogenicity Trial With an Adjuvanted TB Subunit Vaccine (Ag85B-ESAT-6 + IC31)

NCT01049282

Tuberculosis

COMPLETED PHASE1

Safety and Immune Responses After Vaccination With Two Investigational RNA-based Vaccines Against Tuberculosis in Healthy Volunteers

NCT05537038

Tuberculosis

COMPLETED PHASE1

Safety and Immunogenicity of a Candidate Tuberculosis (TB) Vaccine Given to PPD-Negative Adults

NCT00730795

Tuberculosis (TB)

COMPLETED PHASE1

A Safety and Immunogenicity Trial With an Adjuvanted Tuberculosis(TB) Subunit Vaccine

NCT01003093

Tuberculosis

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

PREVENTION

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental vaccine group, Low dose

1 doses of Ad5-105K vaccine (0.1ml) on Day 0

Group Type EXPERIMENTAL

Tuberculosis (TB) vaccine (Ad5-105K)

Intervention Type BIOLOGICAL

1 doses of Ad5-105K vaccine (1 x 10\^8 vp)) on Day 0, Nebulized Inhalation (IH) through mouth

Placebo Group, Low dose

1 doses of placebo (0.1ml) on Day 0

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

1 doses of placebo on Day 0, IH

Experimental vaccine group, High dose

1 doses of Ad5-105K vaccine (0.2ml) on Day 0

Group Type ACTIVE_COMPARATOR

Ad5-105K

Intervention Type BIOLOGICAL

1 doses of Ad5-105K vaccine (2 x 10\^8 vp)) on Day 0, IH

Placebo Group, High dose

1 doses of placebo (0.2ml) on Day 0

Group Type PLACEBO_COMPARATOR

Placebo

Intervention Type BIOLOGICAL

1 doses of placebo on Day 0, IH

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Tuberculosis (TB) vaccine (Ad5-105K)

1 doses of Ad5-105K vaccine (1 x 10\^8 vp)) on Day 0, Nebulized Inhalation (IH) through mouth

Intervention Type BIOLOGICAL

Placebo

1 doses of placebo on Day 0, IH

Intervention Type BIOLOGICAL

Ad5-105K

1 doses of Ad5-105K vaccine (2 x 10\^8 vp)) on Day 0, IH

Intervention Type BIOLOGICAL

Placebo

1 doses of placebo on Day 0, IH

Intervention Type BIOLOGICAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who, in the opinion of the investigator, are able and willing to comply with the requirements of the protocol (e.g., completion of diary cards, returning for follow-up visits).
* Healthy male or female participants aged 18 to 49 years, at the time of obtaining informed consent.
* Written (or thumb printed and witnessed) informed consent obtained from the participant.
* Positive IGRA test with no history of TB disease or treatment.
* Female participants of childbearing potential must have a negative urine pregnancy test at screening and on the day of vaccination. Male and female participants of childbearing potential must agree to use adequate contraception for the entire duration of their participation in the study.
* History of BCG vaccination.

Exclusion Criteria

* Current TB disease, or a history of TB disease and/or treatment for TB (including Tuberculosis Preventive Therapy (TPT)).
* Known history of close or household contact with active TB patient.
* Axillary temperature ≥37.5°C.
* Presence of congenital malformations or developmental disorders, genetic defects, severe malnutrition, etc.
* Lactating women.
* Individuals who smoke more than 10 cigarettes per day within the last 3 months and/or more than 2 cigars per day, and/or vapers who use more than 5 ml of e-liquid daily.
* Individuals with positive HIV, HBV, HCV, or TP (Treponema pallidum) test.
* History of immunosuppressive treatment, cytotoxic treatment, or glucocorticoid treatment, etc. (excluding local treatments, surface treatments for acute non-concurrent dermatitis or spray treatment for allergic rhinitis) in the past 6 months (internal time \<6 months).
* History of, or plans to use, blood/plasma products or immunoglobulins within 60 days prior to study vaccination or at any time during the study period.
* Uncontrolled severe hypertension (at the time of field measurement: systolic blood pressure ≥160 mmHg and diastolic blood pressure ≥100 mmHg).
* Suffering from a serious chronic disease or a condition that is in a progressive stage and cannot be adequately controlled (e.g., thyroid disease), or having known or suspected diseases that at investigators' discretion, may affect vaccination or immunogenicity test results (e.g., diagnosed with asthma within the last 20 years, severe respiratory disease, acute infection or active chronic disease, severe cardiovascular disease, severe liver or kidney disease, malignancy, severe infectious or allergic skin disease).
* History of serious adverse reactions associated with the adenovirus vector-based vaccine and/or history of severe allergic reactions (e.g., systemic allergic reactions) to any component of the study vaccine.
* Immunocompromised individuals with known or suspected immunodeficiency as determined by medical history and/or physical examination (e.g., HIV infection, or a history of pancreatic, liver, spleen, kidney disease, or a history of organ resection).
* Bleeding constitution or condition associated with prolonged bleeding for which IM injection is contraindicated, in the opinion of the investigator.
* History of administration of any vaccine within the past three months.
* History of receiving experimental Mycobacterium tuberculosis (Mtb) vaccines or participation in other interventional studies within 28 days prior to screening and/or during study participation.

Minimum Eligible Age

18 Years

Maximum Eligible Age

49 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes